Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 3, 2012, Pages 159-171

  Jeppesen, Palle Bekker ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Home parenteral nutrition; Short bowel syndrome; Teduglutide

Indexed keywords

ANTIDIARRHEAL AGENT; ELECTROLYTE; GLUCAGON LIKE PEPTIDE 2; PLACEBO; STOMACH SECRETION INHIBITOR; TEDUGLUTIDE;

ABDOMINAL PAIN; APPLICATION SITE INFECTION; CATHETER INFECTION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FECES; FLUID RETENTION; HEADACHE; HUMAN; INTESTINE ABSORPTION; INTESTINE FUNCTION; METABOLIC BALANCE; NAUSEA; ORAL REHYDRATION THERAPY; PARENTERAL NUTRITION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SCORING SYSTEM; SEPSIS; SHORT BOWEL SYNDROME; STOMACH EMPTYING; STOMACH SECRETION; TREATMENT DURATION; URINE; VOMITING;

EID: 84860508349     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11436318     Document Type: Review

References (57)

1. Bahrami J. Yusta B. Drucker D.J. (2010) Erb B activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel. Gastroenterology 138: 2447–2456.
2. Baxter J.P. Fayers P.M. McKinlay A.W. (2006) A review of the quality of life of adult patients treated with long-term parenteral nutrition. Clin Nutr 25: 543–553.
3. Benjamin M.A. McKay D.M. Yang P.C. Cameron H. Perdue M.H. (2000) Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47: 112–119.
4. Bjerknes M. Cheng H. (2001) Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci U S A 98: 12497–12502.
5. Bremholm L. Hornum M. Andersen U.B. Hartmann B. Holst J.J. Jeppesen P.B. (2011) The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept 168: 32–38.
6. Bremholm L. Hornum M. Henriksen B.M. Larsen S. Holst J.J. (2009) Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 44: 314–319.
7. Brubaker P.L. Izzo A. Hill M. Drucker D.J. (1997) Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 272: E1050–E1058.
8. Buchman A.L. Scolapio J. Fryer J. (2003) AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 124: 1111–1134.
9. Cani P.D. Possemiers S. van de Wiele T. Guiot Y. Everard A. Rottier O. et al. (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58: 1091–1103.
10. Cooper J.C. Williams N.S. King R.F. Barker M.C. (1986) Effects of a long-acting somatostatin analogue in patients with severe ileostomy diarrhoea. Br J Surg 73: 128–131.
11. Cortot A. Fleming C.R. Malagelada J.R. (1979) Improved nutrient absorption after cimetidine in short-bowel syndrome with gastric hypersecretion. N Engl J Med 300: 79–80.
12. Crenn P. Coudray-Lucas C. Thuillier F. Cynober L. Messing B. (2000) Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 119: 1496–1505.
13. Drucker D.J. Erlich P. Asa S.L. Brubaker P.L. (1996) Induction of intestinal epithelial proliferation by glucagon- like peptide 2. Proc Natl Acad Sci U S A 93: 7911–7916.
14. Dube P.E. Brubaker P.L. (2007) Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 293: E460–E465.
15. Fleming C.R. Remington M. (1981) Intestinal failure. In: Ed. Hill G.L. (ed.), Nutrition and the Surgical Patient. New York: Churchill Livingstone, pp. 219–235.
16. Goulet O. Joly F. Corriol O. Colomb-Jung V. (2009) Some new insights in intestinal failure-associated liver disease. Curr Opin Organ Transplant 14: 256–261.
17. Guan X. Karpen H.E. Stephens J. Bukowski J.T. Niu S. Zhang G. et al. (2006) GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130: 150–164.
18. Hartmann B. Harr M.B. Jeppesen P.B. Wojdemann M. Deacon C.F. Mortensen P.B. et al. (2000) In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85: 2884–2888.
19. Henriksen D.B. Alexandersen P. Hartmann B. Adrian C.L. Byrjalsen I. Bone H.G. et al. (2009) Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 45: 833–842.
20. Ivory C.P. Wallace L.E. McCafferty D.M. Sigalet D.L. (2008) Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 295: G1202–G1210.
21. Jacobsen O. Ladefoged K. Stage J.G. Jarnum S. (1986) Effects of cimetidine on jejunostomy effluents in patients with severe short-bowel syndrome. Scand J Gastroenterol 21: 824–828.
22. Jeppesen P.B. (2007) Growth factors in short-bowel syndrome patients. Gastroenterol Clin North Am 36: 109–21, vii.
23. Jeppesen P.B. Gilroy R. Pertkiewicz M. Allard J.P. Messing B. O'Keefe S.J. (2011) Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 60: 902–914.
24. Jeppesen P.B. Hartmann B. Hansen B.S. Thulesen J. Holst J.J. Mortensen P.B. (1999 a) Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 45: 559–563.
25. Jeppesen P.B. Hartmann B. Thulesen J. Graff J. Lohmann J. Hansen B.S. et al. (2001) Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120: 806–815.
26. Jeppesen P.B. Hartmann B. Thulesen J. Hansen B.S. Holst J.J. Poulsen S.S. et al. (2000) Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 47: 370–376.
27. Jeppesen P.B. Langholz E. Mortensen P.B. (1999 b) Quality of life in patients receiving home parenteral nutrition. Gut 44: 844–852.
28. Jeppesen P.B. Lund P. Gottschalck I.B. Nielsen H.B. Holst J.J. Mortensen J. et al. (2009) Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009: 616054.
29. Jeppesen P.B. Mortensen P.B. (2000) Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut 46: 701–706.
30. Jeppesen P.B. Sanguinetti E.L. Buchman A. Howard L. Scolapio J.S. Ziegler T.R. et al. (2005) Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54: 1224–1231.
31. Jeppesen P.B. Staun M. Tjellesen L. Mortensen P.B. (1998) Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Gut 43: 763–769.
32. Joly F. Dray X. Corcos O. Barbot L. Kapel N. Messing B. (2009) Tube feeding improves intestinal absorption in short bowel syndrome patients. Gastroenterology 136: 824–831.
33. King R.F. Norton T. Hill G.L. (1982) A double-blind crossover study of the effect of loperamide hydrochloride and codeine phosphate on ileostomy output. Aust N Z J Surg 52: 121–124.
34. Ladefoged K. Christensen K.C. Hegnhoj J. Jarnum S. (1989) Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome [see comments]. Gut 30: 943–949.
35. Lauverjat M. Hadj A.A. Vanhems P. Bouletreau P. Fouque D. Chambrier C. (2006) Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition. Clin Nutr 25: 75–81.
36. Luo M. Fernández-Estívariz C. Manatunga A.K. Bazargan N. Gu L.H. Jones D.P. et al. (2007) Are plasma citrulline and glutamine biomarkers of intestinal absorptive function in patients with short bowel syndrome?, JPEN J Parenter Enteral Nutr 33: 1–7.
37. Marier J.F. Beliveau M. Mouksassi M.S. Shaw P. Cyran J. Kesavan J. et al. (2008) Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol 48: 1289–1299.
38. Marier J.F. Mouksassi M.S. Gosselin N.H. Beliveau M. Cyran J. Wallens J. (2010) Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. J Clin Pharmacol 50: 36–49.
39. Messing B. Crenn P. Beau P. Boutron-Ruault M.C. Rambaud J.C. Matuchansky C. (1999) Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology 117: 1043–1050.
40. Messing B. Pigot F. Rongier M. Morin M.C. Ndeindoum U. Rambaud J.C. (1991) Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome. Gastroenterology 100: 1502–1508.
41. Munroe D.G. Gupta A.K. Kooshesh F. Vyas T.B. Rizkalla G. Wang H. et al. (1999) Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A 96: 1569–1573.
42. Newton C.R. (1978) Effect of codeine phosphate, Lomotil, and Isogel on ileostomy function. Gut 19: 377–383.
43. Nightingale J.M. Lennard Jones J.E. (1993) The short bowel syndrome: what's new and old? Dig Dis 11: 12–31.
44. Nightingale J.M. Lennard Jones J.E. Walker E.R. Farthing M.J. (1992) Oral salt supplements to compensate for jejunostomy losses: comparison of sodium chloride capsules, glucose electrolyte solution, and glucose polymer electrolyte solution. Gut 33: 759–761.
45. Nordgaard I. Hansen B.S. Mortensen P.B. (1994) Colon as a digestive organ in patients with short bowel [see comments]. Lancet 343: 373–376.
46. O'Keefe S.J. Buchman A.L. Fishbein T.M. Jeejeebhoy K.N. Jeppesen P.B. Shaffer J. (2006) Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 4: 6–10.
47. O'Keefe S.J. Peterson M.E. Fleming C.R. (1994) Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. JPEN J Parenter Enteral Nutr 18: 26–34.
48. Orskov C. Hartmann B. Poulsen S.S. Thulesen J. Hare K.J. Holst J.J. (2005) GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 124: 105–112.
49. Pereira-Fantini P.M. Nagy E.S. Thomas S.L. Taylor R.G. Sourial M. Paris M.C. et al. (2008) GLP-2 administration results in increased proliferation but paradoxically an adverse outcome in a juvenile piglet model of short bowel syndrome. J Pediatr Gastroenterol Nutr 46: 20–28.
50. Peters J.H. Wierdsma N.J. Teerlink T. van Leeuwen P.A. Mulder C.J. van Bodegraven A.A. (2007) Poor diagnostic accuracy of a single fasting plasma citrulline concentration to assess intestinal energy absorption capacity. Am J Gastroenterol 102: 2814–2819.
51. Rodrigues C.A. Lennard Jones J.E. Thompson D.G. Farthing M.J. (1989) The effects of octreotide, soy polysaccharide, codeine and loperamide on nutrient, fluid and electrolyte absorption in the short-bowel syndrome. Aliment Pharmacol Ther 3: 159–169.
52. Sigalet D.L. Wallace L.E. Holst J.J. Martin G.R. Kaji T. Tanaka H. et al. (2007) Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 293: G211–G221.
53. Thulesen J. Hartmann B. Hare K.J. Kissow H. Orskov C. Holst J.J. et al. (2004) Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 53: 1145–1150.
54. Tytgat G.N. Huibregtse K. (1975) Loperamide and ileostomy output – placebo-controled double-blind crossover study. Br Med J 2: 667–668.
55. Wojdemann M. Wettergren A. Hartmann B. Hilsted L. Holst J.J. (1999) Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 84: 2513–2517.
56. Wojdemann M. Wettergren A. Hartmann B. Holst J.J. (1998) Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 33: 828–832.
57. Yusta B. Huang L. Munroe D. Wolff G. Fantaske R. Sharma S. et al. (2000) Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119: 744–755.